Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study by Fong, C., Patel, B., Peckitt, C., Bourmpaki, E., Satchwell, L., Cromarty, S., Kidd, S., von Loga, K., Uhlik, M., Begum, R., Rana, T., Waddell, T., Darby, S., Bradshaw, A., Roques, T., Morgan, C., Rees, C., Herbertson, R., Das, P., Thompson, C., Hewish, M., Petty, R., Thistlethwaite, F., Rao, S., Starling, N., Chau, I., Cunningham, D.

Get full text